Regeneron Pharmaceuticals REGN Other products — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's other products — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's other products — revenue?
- Regeneron Pharmaceuticals (REGN) reported other products — revenue of $31.3M in Q1 2026.
- What does other products — revenue mean?
- Total revenue generated from the company's secondary pharmaceutical products outside of its primary core franchises.
- How do you interpret other products — revenue?
- An increase suggests successful commercialization of smaller assets or portfolio diversification, while a decrease may indicate declining legacy product performance or a strategic shift away from non-core therapies.
- How does other products — revenue compare across companies?
- Peers typically report this as 'Other Revenue' or 'Non-Core Product Sales,' and it is often benchmarked against the contribution of primary blockbuster drugs to total revenue.